Onyx Biotec IPO subscription started on Wednesday November 13, and will close on November 18 as per the schedule. The price band is set at ₹58 to ₹61 per share with a face value of ₹10.
Onyx Biotec IPO Subscription Status
Onyx Biotec IPO Subscribed over 3.05x on its first day till 05.00 PM on 13th November.
- Onyx Biotec IPO subscription QIB investors portion is 0x times, while NII subscribed 1.65x times and RII investors subscribed 5.34x times.
- The company has received bids for 96,68,000 shares against 32,00,000 shares on offer on the first day.
- Onyx Biotec IPO Subscribed over 3.05x on day 1.
About Onyx Biotec IPO
On May 13, 2015, Onyx Biotech Limited began its operations in the pharmaceutical market, initially focusing on the supply of sterile water for injection. Over the years, Onyx has become a leading supplier of sterile pharmaceutical products, offering a variety of Dry Powder Injections and Dry Syrups for both domestic and international markets. The company is ranked among the top pharmaceutical companies in India, renowned for providing high-quality products at affordable prices without compromising on quality. Onyx Biotech has two manufacturing facilities, referred to as Unit I and Unit II. Unit I has the capacity to produce 638,889 units of Sterile Water for Injections daily in a single shift. In comparison, Unit II can manufacture 40,000 units of Dry Powder Injection and 26,667 units of Dry Syrup each day. At Onyx Biotech Limited, a dedicated team collaborates to create high-quality medicinal products that are accessible and affordable, ensuring that everyone can receive the treatment they need.
Onyx Biotec IPO Company Financial Report
The company reported revenue of ₹53.87 crores in 2024 against ₹39.62 crore in 2023. The company reported Profit of ₹3.03 crores in 2024 against Profit of ₹1.84 crores in 2023.
Onyx Biotec IPO GMP:
Onyx Biotec IPO GMP was ₹10 as of Wednesday, November 13. That indicates the IPO is trading at ₹71 with ₹10 premium in the grey market against the issue price of ₹61.
